Skip to Main Content

Hematology, Blood & Marrow Transplant, and Cellular Therapy (HBC) Program

The UCSF Hematology, Blood and Marrow Transplant, and Cellular Therapy (HBC) Program is dedicated to providing the most advanced treatment options with care and compassion. Our acclaimed program draws patients from throughout the United States and abroad who seek exceptional and innovative treatment from providers specializing in blood disorders and cancers.

UCSF is also home to a robust research program for hematology, BMT and CAR T-cells. Patients may have the option to participate in clinical trials, including studies of cutting-edge immunotherapy treatments, such as tumor vaccines and CAR T-cell therapy.

CAR T-Cell Therapy

Our clinical and research teams are internationally renowned for their pioneering work in cell-based immunotherapy for cancer. UCSF gained a unique place in the history of cancer immunotherapy when UCSF-affiliated physicians and scientists initially developed and tested the first FDA-approved checkpoint inhibitor ipilimumab (Yervoy) in patients in 2011. We continue to work at the forefront of the field and are actively involved in CAR (chimeric antigen receptor) T-cell treatment and research.

FDA-approved CAR T-cell therapy uses a patient's immune system to fight certain cancers. The therapy is a one-time treatment used when those cancers have resisted all other therapeutic options or have recurred more than once.

CAR T-cell therapy has resulted in long-term remissions for many patients with B-cell non-Hodgkin's lymphoma, B-cell acute lymphoblastic leukemia, and mantle cell lymphoma. Research is ongoing to evaluate it as a treatment for other blood cancers, including multiple myeloma, and solid tumors of the breast, prostate, brain, lungs and other organs.

Comprehensive Cancer Center

As part of the UCSF Helen Diller Family Comprehensive Cancer Center, we offer our cancer patients access to many services, including support groupsexercise and mindfulness classespsychosocial supportsymptom management and much more

Parker Institute for Cancer Immunotherapy

Our program is a member of the Parker Institute for Cancer Immunotherapy, a consortium made up of 10 of the world's leading cancer centers. Its mission is to turn cancer into a curable disease by accelerating the development of breakthrough immune therapies.

Learn more about clinical trials and how they work.

Our locations

Expand Map

    Patient education

    Hematology and BMT Resource Guide

    This hematology and bone marrow transplant (BMT) resource guide provides information about diseases and treatments, employment, insurance and more.

    Autologous Transplant Guide

    Having a blood and marrow transplant (BMT) is a difficult experience. Read this guide to help prepare you and your family and book an appointment today.

    Matched Unrelated Donor Transplantation

    Bone marrow transplantation can be performed using one's own bone marrow or by using another person's bone marrow. Learn more here.

    Our team

    Decorative Caduceus

    Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

    Proportion of participants with treatment-emergent adverse events of CAR-T as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0, revised cytokine release syndromeCRS grading...

    Recruiting

    Decorative Caduceus

    A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (C...

    The primary objective of this access and distribution protocol is to examine the incidence of neutrophil recovery of ≥500/mm3 after cord blood transplantation in a multi-institution setting using CBUs that are not FDA licensed.

    Recruiting

    Decorative Caduceus

    P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

    Rate of dose limiting toxicities (DLT)

    Recruiting

    Decorative Caduceus

    Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disea...

    The Kaplan-Meier method will be used to estimate OS, including medians and confidence intervals. Comparison of OS between treatment arms will be conducted using a one-sided log-rank test stratified with mantle cell lymphoma Intern...

    Recruiting

    Decorative Caduceus

    Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

    Overall survival post-alloHCT via comparison between those testing positive or negative using an optimized molecular monitoring approach.

    Recruiting

    Decorative Caduceus

    Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocat...

    A dose limiting toxicity (DLT) will be defined as an adverse event that are considered by the investigator to be at least possibly related to the study drugs and are observed within the DLT assessment window (Cycle 1, Days 1 to 28...

    Recruiting

    Decorative Caduceus

    Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis ...

    The proportion of responder (complete response (CR) or partial response (PR)) or non-responder at the end of induction using a physician developed response criteria will be reported. Those with non-malignant HLH (nmHLH) will be as...

    Recruiting

    Decorative Caduceus

    Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia

    Grade >= 3 toxicity using Common Terminology Criteria for Adverse Events version 5.0 or severe persistent hematologic toxicity defined as absolute neutrophil count (ANC) < 500/uL OR platelet count < 10,000/uL in participants that ...

    Recruiting

    Decorative Caduceus

    Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

    Toxicities will be classified using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The DLT will be based on the tolerability observed during the first cycle. In order for a patient to be assessed for D...

    Recruiting

    Decorative Caduceus

    A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

    Treatment-emergent adverse events (AEs), treatment-related AEs, and clinically significant changes in laboratory test results will be evaluated

    Recruiting

    Rankings & achievements

    • usnews-neurology

      Among the top hospitals in the nation

    • Best in Northern California and No. 7 in the nation for cancer care

    • Rated high-performing hospital for leukemia, lymphoma & myeloma care

    • 220-2x

      blood and marrow transplants performed each year

    • 1986-2x

      Founded in 1986

    Accreditations & memberships

    • National Cancer Institute

      The National Cancer Institute has designated UCSF a comprehensive cancer center, its highest ranking. This designation is awarded to centers that demonstrate scientific excellence and the ability to conduct cancer research across many disciplines.

    • Commission on Cancer

      UCSF's cancer programs have been accredited by the American College of Surgeons' Commission on Cancer (CoC) since 1933. The CoC is a consortium of groups dedicated to improving cancer patients' survival and quality of life via research, education and better medical care.

    • National Comprehensive Cancer Network

      UCSF is a founding member of the National Comprehensive Cancer Network, an alliance of the world’s top cancer centers. The network brings together leaders in treatment and research to improve the quality, effectiveness and efficiency of cancer care.

    • FACT Accreditation

      Our Hematology, BMT and Cellular Therapy Program is accredited by the Foundation for Accreditation of Cellular Therapy (FACT). FACT-accredited programs follow specific high-quality medical and laboratory processes when providing cellular therapies such as BMT.

    Support services

    ""
    Patient Resource

    Case Management & Social Work

    Connect with a team that can help you find resources, solve problems and advocate for you during treatment at UCSF.

    Patient Resource

    Kôz Hospitality House

    Kôz Hospitality House provides comfortable, reasonably priced accommodations near our Parnassus campus for UCSF patients during their treatment.

    Class

    Mindfulness-Based Stress Reduction Class

    This eight-week class teaches mindfulness practices that can reduce stress and improve your overall health, such as meditation and body awareness.

    Patient Resource

    Patient Relations

    We welcome feedback about your experience at UCSF Health. Find out how to contact us with comments, questions or concerns.

    Patient Resource

    Spiritual Care Services

    Chaplains representing many faiths are available around the clock to provide support, comfort and counsel to patients, families and caregivers.

    Preparing for your appointment

    What to Bring

    • Photo I.D.
    • Health insurance card
    • Insurance authorization, if required
    • Doctor's referral, if required
    • Recent test results related to your condition
    • List of your medications, including dosages, plus any you're allergic to
    • List of questions you may have
    • Device or paper for taking notes

    International Services

    If you live outside the United States and are coming to UCSF for medical treatment, our patient liaisons can help coordinate all aspects of your visit.

    Learn more

    Interpreting Services

    UCSF offers interpreters in various languages, including American Sign Language (ASL), as well as services for deaf, hard-of-hearing and visually impaired patients.

    Learn more

    Hospital Stays

    Make your hospital stay as smooth and comfortable as possible by finding out how to prepare and what to expect.

    Learn more

    Your Doctor Visit

    See our top 10 tips for making your UCSF doctor’s appointment as stress-free and productive as possible.

    Learn more

    Related clinics

    Hemophilia Treatment Center

    400 Parnassus Ave., 4th Floor
    San Francisco, CA 94143

    Cancer Immunotherapy Clinic

    Bakar Precision Cancer Medicine Building

    1825 Fourth St., Fifth Floor
    San Francisco, CA 94158

    Cancer Immunotherapy Toxicity Evaluation (CITE) Program

    Bakar Precision Cancer Medicine Building

    1825 Fourth St.
    San Francisco, CA 94158

    Cancer Symptom Management

    Bakar Precision Cancer Medicine Building

    1825 Fourth St.
    San Francisco, CA 94158

    Cancer Center Redwood City

    2900 Whipple Ave., Suite 130
    Redwood City, CA 94062

    Cancer Center San Mateo

    218 DeAnza Blvd.
    San Mateo, CA 94402

    Psycho-Oncology

    Bakar Precision Cancer Medicine Building

    1825 Fourth St.
    San Francisco, CA 94158

    UCSF-John Muir Health Cancer Center in Berkeley

    Berkeley Outpatient Center

    3100 San Pablo Ave., Suite 280
    Berkeley, CA 94702

    Our research initiatives

    • UCSF-Helen-Diller-Family-Comprehensive-Cancer-Center-Research-2x

      UCSF Helen Diller Family Comprehensive Cancer Center Research

      UCSF is home to a range of research initiatives aimed at improving outcomes for cancer patients everywhere. This includes research on topics such as immunotherapy, BRCA mutations and molecular diagnostic testing.

    Can't find what you're looking for?

    UCSF Help Center

    (888) 689-8273

    Share